家属患肺炎支原体感染对患儿疗效的影响

The Effect of Mycoplasma Pneumoniae Infection on Children’s Curative Effect

目的探究家属患肺炎支原体感染对患肺炎支原体感染患儿疗效的影响,分析患儿患得肺炎支原体感染经治疗后的转归是否与家属的肺炎支原体感染有关。方法选取2018年3月-2019年3月期间医院收治的患肺炎支原体感染患儿及家属各70例作为研究对象,采用随机数字表法分组,对照组及研究组均为35例。研究组为患儿和家属同时进行检查和治疗;对照组为患儿接受治疗,家属未接受治疗,只接受检查,对比两组患儿的治疗效果。结果研究组治疗总有效率为94.29%,对照组总有效率为71.43%,两组治疗有效率比较差异具有统计学意义(P=0.011 <0.05)。对照组、研究组患儿患难治性呼吸道感染发生率分别为34.29%、11.43%,比较差异具有统计学意义(P <0.05)。结论患有肺炎支原体感染的患儿的家庭成员检测肺炎支原体抗体,并治疗患有肺炎支原体感染的成员,对患儿患有呼吸道感染性疾病的机率明显减少,减少患儿的患肺炎支原体感染的机率。

Objective To explore the effect of family members with mycoplasma pneumoniae infection on the efficacy of the children with mycoplasma pneumoniae infection, and analyze whether family members with mycoplasma pneumoniae infection have something to do with the prognosis of the treatment of the children with mycoplasma pneumoniae infection. Methods 70 children and their family members with mycoplasma pneumoniae infection treated in our hospital from March 2018 to March 2019 were selected respectively as the research objects. They were divided into the control group and the research group by means of the random number table, with 35 cases in each group. The children and their family members in the research group were examined and treated at the same time;the children in the control group were treated while their family members are not treated, only examined. The therapeutic effect on the two groups was compared. Results The total effective rate of the research group was 94.29% and that of the control group was 71.43%. The difference in the effective rate of the treatment had statistical significance(P=0.011 < 0.05). The incidence of refractory respiratory tract infection of the children in the control group and research group was 34.29% and 11.43% respectively. The difference had statistical significance.(P < 0.05). Conclusion The examination of mycoplasma pneumoniae antibody and the treatment of mycoplasma pneumoniae infection of the children’s family members significantly reduces the probability of the children with a respiratory infectious disease and mycoplasma pneumoniae infection.